Cambridge neuropsychological test automated battery (CANTAB) is a cognitive function test device that examines memory, learning, attention, motivation, and reaction time in animals and humans. Schizophrenia is a serious mental disorder including positive and negative symptoms as well as cognitive dysfunction. In the present study, we utilized a delayed matching to sample task (DMST), one of the CANTAB programs, to examine cognitive functions in a drug-induced schizophrenia-like cynomolgus monkey model. MK-801, an N-methyl-D-aspartate (NMDA) receptor antagonist, that is known to induce schizophrenia-like symptoms in various species, reduced accuracy rates in the DMST in the monkeys, demonstrating the cognitive impairment from MK-801(20 μg/kg im, n=4). This effect was reversed by D-cycloserine, a partial NMDA agonist, and A776363, a dopamine 1 (D1) receptor agonist(0.1 and 1μg/kg im, n=3). On the other hand, donepezil(100 μg/kg im, n=4), a cholinesterase inhibitor approved as an Alzheimer's disease therapeutic agent, did not affect MK-801-induced cognitive impairment, similarly to the lack of donepezil efficacy on cognitive functions in schizophrenia patients. These results demonstrate the roles of NMDA and D1 but not cholinergic receptors in cognitive functions in MK-801 induced schizophrenia-like symptoms in cynomolgus monkeys.